This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Intrexon Strengthens Leadership In Company's Rapidly Growing Health Sector

GERMANTOWN, Md., Dec. 17, 2013 /PRNewswire/ --  Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Dr. Gregory Frost, currently Chief Executive Officer of Halozyme Therapeutics (Nasdaq: HALO), to head Intrexon's Health Sector, reporting to RJ Kirk.  Dr. Frost's appointment with Intrexon will be effective January 6, 2014. Dr. Samuel Broder, former Director of the National Cancer Institute, has been named Chairman of the Health Sector.


Dr. Frost co-founded Halozyme in 1999 and has served on the Board of Directors and in numerous operational roles, including Chief Scientific Officer since 2002 and CEO since 2010.  For over 15 years, Dr. Frost led the research and development efforts at Halozyme from discovery through commercialization for a number of internal and partnered biotechnology products, as well as facilitating broad alliances with pharmaceutical companies such as Roche and Pfizer.

On Dr. Frost's joining Intrexon, Randal J. Kirk, Chairman and Chief Executive Officer, observed that "I have worked with Greg since 2005 and know him to be among the rarest type of biotech executive, a first-rate scientist with a knowledge base that is as broad as it is deep, an intense curiosity and intensity to solve important healthcare problems with creative biological invention, a passionate commitment to data and the intellectual strength to drive data acquisition and analyze its meaning, a broad industrial comprehension and a proven executive skillset to lead a complex of therapeutic teams from discovery work all the way through product registrations in the U.S. and in Europe.  Equally important, Greg's integrity and work ethic are complementary with our standards at Intrexon and actually exemplary of them.  We know that we shall have a terrific working relationship out the gate and I look forward to working with Greg to deliver on the promise of applying Intrexon's unique technologies to important healthcare needs."

Dr. Frost commented, "Having worked very closely with Mr. Kirk and knowing much of the team at Intrexon, I have developed a profound level of respect for both the people as well as the immense potential of their unique technology platforms.  The ability to solve the historical challenges of DNA and cellular-based therapies through synthetic biology could very well solve many healthcare challenges previously deemed untreatable. I am passionate about maximizing the potential of these platform technologies for patients and shareholders."   

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs